Starget Pharma

What Starget Pharma does

Starget Pharma is a clinical-stage radiopharmaceutical company developing a portfolio of Smart Targeted Radioligands (STRs) for precision oncology, with primary focus on hard-to-heal metastatic cancers including sarcoma, neuroendocrine tumors, malignant melanoma, and hepatocellular carcinomas. The company was founded in 2019 and is headquartered in Tel Aviv, Israel, with U.S. operations anchored through a strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Louisiana. Its lead clinical asset is DOTA-PTR-58, a first-in-class somatostatin receptor type 3 (SSTR3)-targeted theranostic pair combining Ga-68 imaging and Lu-177 therapy, advancing through a Phase 1b trial at MD Anderson and other U.S. cancer centers.

The core technology is an AI-powered Peptide Backbone Dynamics platform that integrates in silico computational modeling with proprietary peptide backbone cyclization to engineer 2D and 3D structural properties of peptide pharmacophores, enabling rapid identification of radioligand candidates with enhanced affinity, selectivity, and pharmacokinetic properties. The platform is supported by modular sub-technologies including the Radio Dynamics Toolbox for isotope chelation optimization, Auxiliary Molecular Entities for bioavailability, and Physical Boosters for biodistribution tuning, and is structured to be isotope-agnostic across common and rare alpha-emitters such as Astatine-211, Lead-212, and Actinium-225. Backbone cyclization IP and somatostatin analog know-how trace back to the founders' prior work at Peptor and to Professor Chaim Gilon's pioneering academic research.

Starget's business model is pre-commercial: the company is venture-backed and funds clinical development and U.S. operational scaling through equity financing rather than product sales, with future revenue anticipated from drug commercialization or licensing following regulatory approval. Go-to-market in the current phase is conducted through clinical trial partnerships with major U.S. cancer centers (MD Anderson, Ochsner Health, LSU Feist Weiller), strategic alliances for manufacturing and isotope supply (CMIT, Nusano), and investor and economic development relationships (Louisiana Growth Fund, Cancer Focus Fund, BRF, Ilex Medical). Customer segments are exclusively healthcare-provider oncology centers during clinical development, with no commercial pricing disclosed at this stage.

Name

Starget Pharma

Legal name

Starget Pharma Inc.

Website

https://stargetpharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Starget Pharma is a clinical-stage radiopharmaceutical company developing AI-powered Smart Targeted Radioligands, led by a first-in-class SSTR3-targeted theranostic (DOTA-PTR-58) for hard-to-heal metastatic cancers including sarcoma, neuroendocrine tumors, melanoma, and hepatocellular carcinoma.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals / Targeted Radioligand Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Targeted radioligand therapy
• Radiopharmaceutical drug development
• Peptide drug discovery
• Cancer theranostics
• AI drug design

Headquarters

HQ city

Ramat Hasharon

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Others

Revenue model

1. Radiopharmaceutical Drug Development: Pre-revenue clinical-stage company developing peptide radioligand therapies for cancer treatment. Revenue will be generated through drug commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Starget Pharma develops a portfolio of Smart Targeted Radioligands (STRs)—peptide-based radiopharmaceuticals that combine a radionuclide payload with a tumor-targeting peptide ligand—for precision treatment of hard-to-heal metastatic cancers. Discovery is powered by a proprietary AI-driven Peptide Backbone Dynamics platform that integrates in silico computational modeling with peptide backbone cyclization to engineer 2D/3D molecular conformations. The lead clinical candidate is DOTA-PTR-58, a first-in-class SSTR3-targeted theranostic pair advancing through a Phase 1b trial in sarcoma, neuroendocrine tumors, melanoma, and hepatocellular carcinomas.

Product overview

Starget Pharma is a clinical-stage radiopharmaceutical company developing a portfolio of Smart Targeted Radioligands (STRs) for precision oncology. The core offering is built on an AI-powered Peptide Backbone Dynamics Platform that uses proprietary backbone cyclization to transform peptides into next-generation radiopharmaceuticals. The lead product is DOTA-PTR-58, a first-in-class SSTR3-targeted theranostic pair in Phase 1b development for sarcoma, neuroendocrine tumors, melanoma, and hepatocellular carcinomas. Supporting the core platform are modular technologies including Backbone Cyclization, Radio Dynamics Toolbox, Auxiliary Molecular Entities, and Physical Boosters. The company plans multiple clinical entries in 2026 across its pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• DOTA-PTR-58 (SSTR3-Targeted Theranostic Pair) First-in-class superagonist radioligand with sub-nanomolar affinity targeting somatostatin receptor type 3 (SSTR-3), a receptor highly expressed across sarcoma, melanoma, neuroendocrine tumors, and hepatocellular carcinomas. DOTA-PTR-58 is a theranostic pair: imaging with Ga-68 and therapy with Lu-177, with a follow-on program for therapy with Ac-225. The lead compound is advancing through a Phase 1b clinical trial for cancer patients with limited treatment options.
• Smart Targeted Radioligands (STRs)

Quantifiable outcome

• First-in-human data demonstrated promising safety and good tumor uptake for DOTA-PTR-58
• +1 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Center for Molecular Imaging and Therapy (CMIT)coreStrategic or Co-development Partner · 18 February 2026Strategic collaboration to develop next-generation peptide radioligand therapies for cancer. CMIT provides translational and manufacturing infrastructure including molecular imaging, radiochemistry, preclinical and clinical research, and radiopharmaceutical manufacturing and distribution. CMIT's parent entity BRF also participated as an investor in the Series A round.
• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 23 October 2024Phase 1b clinical trial site for DOTA-PTR-58 targeting SSTR3-positive tumors. Dr. Jordi Rodón serves as Principal Investigator. The Cancer Focus Fund was established in collaboration with MD Anderson.
• NusanocoreTechnology or Integration · 17 October 2024Supply agreement to provide radioisotopes for Starget's Smart Targeted Radioligand development from discovery through commercialization. Includes both common radioisotopes and rare alpha particle-emitters such as Astatine-211, Lead-212, and Actinium-225. Nusano's production platform opening in 2025 in Utah will be capable of generating more than 25 radioisotopes.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Novartis (Radioligand Therapy): Novartis commercializes Lutathera (SSTR2-targeted) and Pluvicto (PSMA-targeted), the two leading approved radioligand therapies, and acquired Advanced Accelerator Applications (AAA) for $3.9B. Direct reference point for the regulatory, commercial, and competitive landscape Starget's SSTR3 program will face.

Direct peers

• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing theranostic pairs (notably Illuccix for PSMA imaging) with an active pipeline of targeted radioligands. Closely comparable theranostic platform model and commercial channel dynamics.
• Lantheus Holdings: Radiopharmaceutical company with commercial diagnostics (e.g., PYLARIFY for PSMA imaging) and a growing therapeutic radioligand pipeline. Directly comparable theranostic + isotope-agnostic platform approach.
• POINT Biopharma: Clinical-to-commercial radiopharmaceutical company developing targeted radioligands across multiple tumor types (acquired by Eli Lilly for $1.4B). Closely comparable clinical-stage radioligand development model and multi-indication strategy.
• ITM Isotope Technologies Munich: Developer of therapeutic radioisotopes (notably Lu-177) and targeted radiopharmaceuticals including Solucin (SSTR-targeted) for NETs. Direct peer in peptide-based, SSTR-family radioligand development with vertical isotope manufacturing.
• Fusion Pharmaceuticals: Clinical-stage radioconjugate company developing targeted alpha- and beta-emitting therapies (acquired by AstraZeneca for ~$2.4B). Closely comparable targeted radioligand platform with strong pharma-exit precedent.
• RayzeBio: Clinical-stage radiopharmaceutical company developing actinium-225-based targeted radioligand therapies (acquired by Bristol-Myers Squibb for $4.1B). Comparable targeted alpha-emitter radioligand model and major pharma M&A benchmark.
• Ipsen (Somatuline / Somatostatin franchise): Markets Somatuline Depot (lanreotide), a leading somatostatin analog for NETs and acromegaly. Direct reference point for the somatostatin receptor pharmacology space Starget's SSTR3 program addresses.

Emerging players

• Bicycle Therapeutics: Clinical-stage company developing bicyclic peptide-based targeted therapies for oncology. Comparable peptide-engineering approach to Starget's backbone-cyclized peptides, though applied to non-radiopharmaceutical conjugates.
• Aktis Oncology: Clinical-stage radiopharmaceutical company developing alpha-emitting targeted radioconjugates. Comparable emerging platform model focused on next-generation radioligands against validated tumor targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@stargetpharma
• LinkedInlinkedin.com/company/stargetpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Starget Pharma